Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This project will optimise the management of chemotherapy-induced nausea and vomiting, with improvements in nausea and vomiting scores, quality of life and appetite expected in participants benefiting from the intervention. In all cases, the use of complementary methods is recommended and improves the management of people with cancer because they offer a person-centred approach.
The aim is to evaluate the efficacy of inhalation of a mixture of ginger and lemon Essential Oils (EO) versus placebo in addition to conventional antiemetic treatments on the intensity of chemo-induced nausea during the acute phase D1 (H24) of its onset in patients with C1 haematological malignancies.
This multicentre study will be carried out in 5 establishments (haematology and oncology care sectors), which represents a very high potential for inclusion.
In addition, the investigator expect a very high acceptance rate for this study. In fact, in the context of CINV, this care strategy may meet a patient's expectation of symptoms (nausea, vomiting) that they find difficult to manage. Finally, it is known that patients in these care sectors are very keen on supportive care to improve their quality of life, so this is a potentially very interesting opportunity without any particular risk that is offered to participants in this study.
A nurse and a doctor with a postgraduate diploma in aromatherapy are coordinating the team, with the support of a nurse trained in evidence-based practice research methodology. Institutional procedures drawn up by the team at Limoges University Hospital describe the general procedure for using aromatherapy in a scientific and safe way, the protocols that can be used to describe the operating methods, the traceability of the manufacture of the mixtures and their administration, and the evaluation of their effectiveness. Supporting documents, an information note and a monitoring sheet have been created and are being used.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Blend of ginger and lemon essential oils | Active Comparator | The experimental group will benefit from conventional management of NVCI (antiemetic prophylaxis in accordance with ESMO international recommendations) plus an aromastick of ginger and lemon essential oils renewed with each course of chemotherapy. Patients were included for 3 cycles of chemotherapy (C1, C2, C3). |
|
| Neutral oil | Placebo Comparator | The control group will receive conventional management (antiemetic prophylaxis according to international recommendations, ESMO) of NVCI plus a placebo of aromastick containing a neutral, odourless oil, renewed with each course of chemotherapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| "Blend of ginger and lemon essential oils", "Neutral oil" | Combination Product | Patients will be given aromasticks to inhale the blend of essential oils. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy of inhaled aromatherapy on acute nausea | To assess difference of nausea intensity score measured by MAT Tool between groups oils (EO) of ginger and lemon versus placebo in addition to addition to conventional antiemetic treatments on intensity of chemo-induced nausea during the acute phase D1 (H24) of onset in patients with haematological malignancies C1 haematological malignancies. MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset. | 1 month, 2 months and 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy of inhaled aromatherapy on vomiting frequency | To evaluate difference of vomiting fréquency measure by MAT Tool between groups. MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CH BRIVE | Recruiting | Brivé | 19100 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019337 | Hematologic Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Double-blind randomised controlled trial
Not provided
Not provided
Not provided
| 1 day, 1 month |
| Efficacy of inhaled aromatherapy on acute nausea between 4 days and 1 month | To assess difference of nausea intensity score measured by MAT Tool between groups. MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset. | 4 days, 1 month |
| Efficacy of inhaled aromatherapy on vomiting frequency between 4 days and 1 month | To evaluate difference of vomiting fréquency measure by MAT Tool between groups. MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset. | 4 days, 1 month |
| Efficacy of inhaled aromatherapy | To compare the efficacy of inhaled aromatherapy on the evolution of nausea intensity in the acute phase acute phase (D1) and then the delayed phase (D4) chemotherapy cycles (C1, C2 and C3). MAT is used to self-assess the prevention and control of chemotherapy-induced nausea and vomiting. It comprises 2 evaluation parts: the first is a Likert scale assessing the intensity of chemotherapy-induced nausea (0-10), and the second is a record of the frequency of vomiting in the acute (H24) and delayed (H96) phases of chemo-induced nausea and vomiting onset. | 1 month, 2 months and 3 months |
| Anticipatory nausea | Compare the intensity of chemo-induced nausea. Compared the mean difference of anticipatory nausea intensity score measured by a Likert scale (ranging from 0-10 with zéro none and 10 as much as possible) between groups before the start of each cycle of chemotherapy (C1, C2, C3) between groups. | 1 month, 2 months and 3 months |
| Compare the proportion of chemically-induced emesis | Compare the proportion of chemically-induced emesis before the start of each cycle of chemotherapy (C1, C2, C3) between groups. | 1 month, 2 months and 3 months |
| Independent determinants of the presence of nausea then vomiting | To identify, in patients who received aromatherapy, the association between independent determinants of the presence of nausea then vomiting at the acute phase (D1) and at the delayed phase (D4) of the first cycle of chemotherapy (C1) (sex, age, anticipation of CINV, nausea terrain, history of nausea/vomiting, history of chemotherapy, motion sickness, tolerance of EO odour). | 1 month, 2 months and 3 months |
| Compare and describe the use of antiemetics use of antiemetics | Compare and describe the use of antiemetics use of antiemetics and write down the use of EO inhalations EO inhalations "if needed" during the acute (D1), delayed (D4) and anticipated phase of CINV (H0) during the 3 cycles of chemotherapy (C1, C2 and C3). | 1 month, 2 months and 3 months |
| Impact of inhaled aromatherapy on quality of life | Compare quality of life between the two groups at each each cycle of chemotherapy (C1,C2 and C3). Difference of quality of life score (EORTC QLQC30) between groups at each cycle. EORTC QLQC 30 is European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire. This self-questionnaire, validated in French, assesses quality of life specific to cancer. It is intended for all cancer patients, regardless of location. EORTC QLQC 30 contains 30 items and assesses 15 dimensions of quality of life :
| 1 month, 2 months and 3 months |
| Efficacy of inhaled aromatherapy on dietary intake | To compare the effect of inhalation of ginger + lemon EO versus placebo in addition to conventional antiemetic treatments on diet during C1, C2, C3. Difference of dietary intake measured by SEFI scale between groups. SEFI (Score d'Evaluation Facile des Ingesta - Ingesta Easy Evaluation Score) / LA description : SEFI is a visual assessment, by the patient himself or with the help of a caregiver, of his food intake, using an analog scale (0 to 10), or a choice of portions consumed. | 1 month, 2 months and 3 months |
| Chu La Reunion | Recruiting | La Réunion | 97448 | France |
|
| University Hospital, Limoges | Recruiting | Limoges | 87042 | France |
|
| Ch Poissy | Recruiting | Saint-Germain-en-Laye | 78100 | France |
|